Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Evaluating a Therapy for Rare Midgut Tumors
Clinical Breakthroughs

Evaluating a Therapy for Rare Midgut Tumors

By Anna WilliamsFeb 20, 2017
Share
Facebook Twitter Email
Al-Benson-MD
Al Benson, MD, professor of Medicine in the Division of Hematology/Oncology, was a co-author of the paper, which evaluated a therapy for advanced midgut neuroendocrine tumors.

An experimental drug improved progression-free survival rates for patients with advanced midgut neuroendocrine tumors — a rare cancer of the small intestine and colon — over a standard therapy, according to a recent global phase III clinical trial. Northwestern Medicine was a major participant in the trial, including faculty from the Division of Hematology/Oncology and faculty specializing in nuclear medicine.

The study, published in the New England Journal of Medicine, was co-authored by Al B. Benson III, MD, FACP, FASCO, professor of Medicine in the Division of Hematology/Oncology and associate director for cooperative groups at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Patients with midgut neuroendocrine tumors are typically first treated with a somatostatin analogue. But if they experience disease progression after such therapy, there are limited options for second-line treatment. Five-year survival rates for patients with metastatic disease are estimated to be less than 50 percent.

In the current trial, investigators randomly assigned 229 patients with a progressive form of the disease to receive either a higher dose of a somatostatin analogue called octreotide long-acting repeatable (LAR) or a drug called 177Lu-Dotatate, plus standard care. 177Lu-Dotatate, which is not yet commercially available in the United States, is a type of peptide receptor radionuclide therapy (PRRT), a targeted treatment that delivers radiation directly to tumor cells.

The investigators found that patients in the 177Lu-Dotatate group had noticeably improved outcomes. Trial participants who received 177Lu-Dotatate had a 65.2 percent estimated rate of progression-free survival by month 20, compared to 10.8 percent for those treated with octreotide LAR alone. Furthermore, 177Lu-Dotatate showed an 18 percent response rate, compared to 3 percent in the control group.

Overall, the relative risk of disease progression or death for patients who were assigned 177Lu-Dotatate was 79 percent lower than the risk with high-dose octreotide LAR.

The most common adverse effects were nausea and vomiting — a result of simultaneous infusions of nephroprotective amino acids — and there was no evidence of kidney damage.

The drug has been submitted for FDA approval.

“Northwestern Medicine is a major site for the treatment of neuroendocrine tumors,” Benson said. “Upon FDA approval, we look forward to being able to routinely offer our patients this therapy as an important advancement in care.”

The research was supported by Advanced Accelerator Applications, which developed the drug. Benson reported grant support from Advanced Accelerator Applications during the conduct of the study.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Lieber Receives VA Rehabilitation Research and Development Award 

Mar 13, 2023

Comments are closed.

Latest News

Celebrating Feinberg’s 2023 Match Day

Mar 17, 2023

Predicting Risk of Blood Clots in Brain Tumors

Mar 16, 2023

Understanding How Exercise Induces Systemic Metabolic Benefits

Mar 15, 2023

Future Directions in Continuing Medical Education

Mar 14, 2023

Lieber Receives VA Rehabilitation Research and Development Award 

Mar 13, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
_5NM1245
230204_SERIO_MANDELL_Feinberg_Formal_0928
_5NM1715
_5NM0526
_5NM1026 (1)
_5NM1906
_5NM2173
230204_SERIO_MANDELL_Feinberg_Formal_0896
230204_SERIO_MANDELL_Feinberg_Formal_1113
230204_SERIO_MANDELL_Feinberg_Formal_1868
230204_SERIO_MANDELL_Feinberg_Formal_1237
230204_SERIO_MANDELL_Feinberg_Formal_1172

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.